Arcutis Biotherapeutics (ARQT) Financials

The income statement for Arcutis Biotherapeutics Inc (ARQT) provides a snapshot of the company's financial performance over a specific period. It shows the revenues generated by the company, the costs associated with generating those revenues, and the resulting net income. In recent years, Arcutis Biotherapeutics Inc has recorded significant growth in its total revenue, largely driven by its strong product portfolio and expanding market presence. The company continues to invest in research and development to drive innovation and maintain its competitive edge in the industry.

EBIT, or earnings before interest and taxes, is a measure of a company's profitability that shows how much it generates in operating income before accounting for interest and tax expenses. Arcutis Biotherapeutics Inc has been successful in improving its EBIT margin over the years, displaying efficient cost management and increasing operating efficiency.

EBITDA, or earnings before interest, taxes, depreciation, and amortization, is another profitability measure that provides a clearer picture of a company's operating performance. By excluding non-cash expenses like depreciation and amortization, it enables investors to assess a company's core operating performance more accurately. Arcutis Biotherapeutics Inc's robust EBITDA performance is a testament to its strong operational capabilities and efficiency.

Gross profit represents the revenue remaining after deducting the costs directly associated with producing the goods or services sold by the company. Arcutis Biotherapeutics Inc has consistently maintained a healthy gross profit margin, indicative of its ability to effectively manage production costs and generate sustainable profits.

Net income attributable to stockholders is the company's profit after deducting expenses, taxes, and other costs during a given period. Arcutis Biotherapeutics Inc has shown consistent growth in net income, demonstrating its ability to generate strong returns for its shareholders.

Total revenue represents the sum of all revenues generated by the company during a specific period. Arcutis Biotherapeutics Inc's total revenue has exhibited a positive growth trajectory, driven by strong sales across its product portfolio and successful market penetration.

The balance sheet provides an overview of a company's financial position, including its assets, liabilities, and stockholders' equity. Arcutis Biotherapeutics Inc's balance sheet reflects its strong financial health and stability. The company has a substantial asset base, with a focus on research and development as well as the commercialization of its products.

Cash equivalents refer to highly liquid assets that can be readily converted into cash, such as short-term investments. Arcutis Biotherapeutics Inc maintains a healthy amount of cash equivalents, which provides the company with the flexibility to fund its operations and pursue growth opportunities.

Net debt represents a company's total debt minus its cash and cash equivalents. Arcutis Biotherapeutics Inc has diligently managed its debt levels and strives to maintain a strong balance sheet with a comfortable debt-to-equity ratio, providing financial stability in the long term.

Stockholders' equity represents the residual interest in the company's assets after deducting liabilities. Arcutis Biotherapeutics Inc's stockholders' equity has shown steady growth, reflecting the confidence of investors in the company's performance and future prospects.

Total assets include all the resources owned by the company, such as cash, inventory, property, and equipment. Arcutis Biotherapeutics Inc's total assets have increased consistently, reflecting its commitment to expanding its operations and investing in research and development.

Total debt comprises all the financial obligations owed by the company, including long-term and short-term debt. Arcutis Biotherapeutics Inc maintains a prudent approach to debt management, ensuring that its debt levels are sustainable and do not pose a significant risk to its financial position.

Total liabilities represent all the financial obligations owed by the company, including both short-term and long-term liabilities. Arcutis Biotherapeutics Inc has a well-managed liability structure, which is crucial for its financial stability and ability to meet its obligations.

Cash flow refers to the movement of cash within a company, encompassing cash inflows and outflows. Arcutis Biotherapeutics Inc's cash flow is closely monitored as it provides insights into the company's ability to generate cash from its operating activities and invest in future growth.

Financing cash flow represents the cash flow resulting from activities related to the company's financing, such as issuing or repurchasing stock, paying dividends, or obtaining or repaying debt. Arcutis Biotherapeutics Inc's financing cash flow shows the company's ability to raise capital for its growth initiatives and rewards for its shareholders.

Free cash flow is a measure of a company's financial performance that indicates its ability to generate cash after accounting for capital expenditures and operational expenses. Arcutis Biotherapeutics Inc has been successful in generating positive free cash flow, demonstrating its efficient use of capital and strong cash generation capacity.

Investing cash flow relates to the cash flow resulting from activities related to the company's investments, such as the acquisition or sale of property, plant, and equipment or investments in other companies. Arcutis Biotherapeutics Inc's investing cash flow reflects its strategic investments in research and development, as well as potential acquisitions to complement its product portfolio and drive future growth.

Operating cash flow represents the cash generated from a company's core business operations. Arcutis Biotherapeutics Inc has reported consistent positive operating cash flow, which indicates the company's ability to generate cash from its day-to-day activities and support its ongoing operations.